STERIS plc
STE Healthcare Medical Devices
STERIS plc’s revenue for fiscal 2026 (year ended March 2026) was $5.9 billion, up 8.73% from fiscal 2025. In the quarter to June 2026, revenue grew 7.30%, EPS grew 13.9%, free cash flow fell 14.4% and total debt was flat, each against the same quarter a year earlier. Member of the S&P 500; dividend growth for ten consecutive years, revenue growth for ten, operating cash flow growth for three.
Follow STE
STERIS plc (STE) Revenue
STERIS plc's revenue for fiscal 2026 was $5.9B, up 8.73% from $5.5B in fiscal 2025. Over the twelve months to 30 June 2026 it was $6.0B. Over the past ten years it has ranged from $1.9B (fiscal 2015) to $5.9B (fiscal 2026) — the current reading is the highest in ten years. Revenue has risen for 11 consecutive fiscal years. STERIS plc ranks 10th of 140 Medical Devices companies by revenue.
Revenue, annual
Embed this chart
Annual newest first
| Period | Revenue | Change |
|---|---|---|
| FY2026 | $5.9B | 8.73% |
| FY2025 | $5.5B | 6.24% |
| FY2024 | $5.1B | 13.28% |
| FY2023 | $4.5B | 7.41% |
| FY2022 | $4.2B | 35.91% |
| FY2021 | $3.1B | 2.53% |
| FY2020 | $3.0B | 8.94% |
| FY2019 | $2.8B | 6.19% |
| FY2018 | $2.6B | 0.28% |
| FY2017 | $2.6B | 16.71% |
Quarterly newest first
| Period | Revenue | Change |
|---|---|---|
| Jun 2026 | $1.5B | (6.02%) |
| Mar 2026 | $1.6B | 6.16% |
| Dec 2025 | $1.5B | 2.46% |
| Sep 2025 | $1.5B | 4.97% |
| 42 more quarters | Free account |
Against its own ten years
Revenue against peers
| Company | Revenue |
|---|---|
| GEHC GE HealthCare Technologies Inc. compare | $21.3B |
| PHG Koninklijke Philips N.V. compare | $20.6B |
| SNN Smith & Nephew SNATS, Inc. compare | $10.5B |
| ZBH Zimmer Biomet Holdings, Inc. compare | $8.5B |
| STE STERIS plc | $6.0B |
| DXCM DexCom, Inc. compare | $5.0B |
| GMED Globus Medical, Inc. compare | $3.1B |
| BIO.B Bio-Rad Laboratories, Inc. compare | $2.6B |
| PEN Penumbra, Inc. compare | $1.5B |
What Revenue is
Revenue tells an investor how much a company brought in from selling its goods and services over a period, before any costs are taken out.
Reported line item
More on STE
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement